Yeni Koronavirüs İnfeksiyonu: COVID-19

coksuer, fevziye; Çiftçi, Ergin

doi:10.5578/flora.202002

Yeni Koronavirüs İnfeksiyonu: COVID-19

Ergin ÇİFTÇİ, (Ankara Üniversitesi, Tıp Fakültesi, Çocuk Sağlığı ve Hastalıkları Anabilim Dalı, Çocuk İnfeksiyon Hastalıkları Bilim Dalı, Ankara, Türkiye)

Fevziye ÇOKSÜER (Ankara Üniversitesi, Tıp Fakültesi, Çocuk Sağlığı ve Hastalıkları Anabilim Dalı, Çocuk İnfeksiyon Hastalıkları Bilim Dalı, Ankara, Türkiye)

Flora İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Dergisi

4 0

Yıl: 2020 Cilt: 25 Sayı: 1 Sayfa Aralığı: 9 - 18 Metin Dili: Türkçe DOI: 10.5578/flora.202002 İndeks Tarihi: 29-10-2020

Yeni Koronavirüs İnfeksiyonu: COVID-19

Öz:

Koronavirüsler (CoV) zarflı, tek zincirli pozitif RNA virüsleri olup, oldukça geniş bir aile oluştururlar. İnsanlarda yaygın hastalık yaptığıbilinen 229E, OC43, NL63 ve HKU1 türleri genellikle hafif orta şiddette solunum yolu infeksiyonlarına sebep olurken 2002 yılında “şiddetliakut solunum sendromu (SARS)”, 2012 yılında “Orta Doğu Solunum Sendromu (MERS)” etkeni olmak üzere iki yeni koronavirüs ortayaçıkmıştır. Son olarak 2019 yılında COVID-19 hastalığına neden olan SARS-CoV-2 tanımlanmıştır. Her yaştan insan COVID-19 infeksiyonuna duyarlıdır. Ancak yaşlılar ve altta yatan kronik hastalıkları olanlarda COVID-19 infeksiyonuna duyarlılık artmıştır. COVID-19 infeksiyonunun tedavisinde spesifik antiviral ilaç yoktur. Bu nedenle tedavi stratejisi daha çok destek tedavi ve komplikasyonların önlenmesineyöneliktir. COVID-19 infeksiyonundan korunmanın temel yolu, öncelikle infeksiyonu olan kişi ile temastan kaçınmaktır. COVID-19 hastalığıtanımlandıktan sonra bulunduğu bölgeyle sınırlı kalmamış ve olgu sayısı giderek artarak kıtalar arası bildirimler olmuştur. COVID-19 yüksekpatojenitesi olan bir solunum virüsüdür ve günümüzde küresel anlamda halk sağlığı için ciddi bir tehdit oluşturmaktadır. Tehdidin bertarafedilmesi için virüsün kaynağının açıklığa kavuşturulması, özgül, etkili tedavilerin ve güvenli bir aşının geliştirilmesi gerekmektedir. Virüsünyayılımının engellenmesi için de sürveyansın aktif bir şekilde yapılması, hasta bakımında uygun infeksiyon kontrol yöntemlerinin sıkı birşekilde uygulanması kritik bir öneme sahiptir

Anahtar Kelime:

Novel Coronavirus Infection: COVID-19

Öz:

Coronaviruses (CoV) are enveloped, single-chain positive RNA viruses constituting a fairly large family. 229E, OC43, NL63 and HKU1 species are common in humans, often causing mild to moderate respiratory infections. On the other hand, new coronaviruses have emerged, causing severe respiratory infection such as “severe acute respiratory syndrome” (SARS) in 2002 and “Middle East respiratory syndrome” (MERS) in 2012. The most recent coronavirus, SARS-CoV-2, causing COVID-19 disease was identified in 2019. While people of all ages are susceptible to COVID-19 infection, those with underlying chronic diseases and elderly age have increased susceptibility. There is no specific antiviral drug for COVID-19 infection. Therefore, treatment strategy is mostly aimed at supportive treatment and prevention of complications. The main protection measure is to avoid contact with the person infected with COVID-19. Following the identification of COVID-19 disease, it exceeded the region where it was located, the number of cases increased gradually, and intercontinental reports were made. COVID-19 is a highly pathogenic respiratory virus threatening global public health today. In order to eradicate the virus, it is necessary to clarify the source of the virus, to develop specific, effective treatments and a safe vaccine. Effective surveillance and appropriate infection control measures are critical to prevent the spread of the virus.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık

1. Lu R, Yu X, Wang W. Characterization of human coronavirus etiology in Chinese adults with adults with acute upper respiratory tract infection by real-time RT-PCR assays. PLoS One 2012;7(6):e38638.
2. Zhou Y, Yang Y, Huang J, Jiang S, Du L. Advances in MERSCoV vaccines and therapeutics based on the receptor-binding domain. Viruses 2019;11(1).
3. McIntosh, Perlman S. Coronaviruses, including severe acute respiratory syndrome (SARS) and middle east respiratory syndrome (MERS). In: Bennett JE, Dolin R, Blaser MJ (eds). Principles and Practice of Infectious Diseases. 8th ed. Philadelphia: Elsevier-Saunders, 2015:1928-36.
4. WHO. Clinical management of severe acute respiratory infection when Novel coronavirus (nCoV) infection is suspected: interim guidance. Jan 11, 2020. https://www.who. int/internalpublications-detail/clinical-management-of-severe-acute-respiratoryinfection-when-novel-coronavirus-(ncov)-infection-is-suspected (accessed Jan 20, 2020).
5. Al-Tawfiq JA. Middle East respiratory syndrome- coronavirus infection: an overview. J Infect Public Health 2013;6(5):319-22.
6. Holmes KV, Dominguez SR. The new age of virus discovery: genomic analysis of a novel human betacoronavirus isolated from a fatal case of pneumonia. MBio 2013;4(1):e00548-12.
7. Chan PK, Chan MC. Tracing the SARS-coronavirus. J Thorac Dis 2013;5:118-21.
8. Peiris JS, Yuen KY, Osterhaus AD, Stöhr K. The severe acute respiratory syndrome. N Engl J Med 2003;349:2431-41.
9. Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD,Fouchier RA. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 2012;367(19):1814-20.
10. Chan KH, Chan JF, Tse H, et al. Cross-reactive antibodies in convalescent SARS patients’ sera against the emerging novel human coronavirus EMC (2012) by both immunofluorescent and neutralizing antibody tests. J Infect 2013;67(2):130-40.
11. de Groot RJ, Baker SC, Baric RS, et al. Middle East respiratory syndrome corona-virus (MERS-CoV); announcement of the Coronavirus Study Group. J Virol 2013;87(14):7790-2.
12. Infection prevention and control during health care for probable or confirmed cases of Middle East respiratory syndrome coronavirus (MERS-CoV) infection: interim guidance, updated October 2019. Geneva: World Health Organization; 2019 (WHO/MERS/IPC/15.1 Rev. 1; https://apps.who.int/ iris/handle/10665/174652, accessed 17 January 2020).
13. World Health Organization. Pneumonia of unknown cause-China. 2020 (https://www.who.int/csr/don/05-january -2020-pneumonia -of-unkown-cause-china/en)
14. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China:a descriptive study. January 29, 2020 https://doi.org/10.1016/S0140- 6736(20)30211-7
15. Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet.2020. https ://doi.org/10.1016/ S0140-6736(20)30154-9
16. Kristian G , Andrew R, Lipkin W, Edward C, Robert F. The proximal origin of SARS-CoV-2. Nature Medicine 2020, 17 March.
17. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020 Mar 11:S0140-6736(20)30566-3. doi: 10.1016/S0140-6736(20)30566-3.
18. Xu Y, Li X, Zhu B, et al. Characteristics of pediatric SARSCoV-2 infection and potential evidence for persistent fecal viral shedding. Nat Med (2020). https://doi.org/10.1038/ s41591-020-0817-4
19. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus–infected pneumonia. N Engl J Med 2020 Jan 29.
20. Huang C, Wang Y, Li X. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; published online Jan 24. https://doi.org/10.1016/ S0140–6736(20)30183–5.
21. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020. https ://doi.org/10.1016/ S0140-6736(20)30183 -5.
22. Stanley P. Another decade, another coronavirus. N Engl J Med 2019. https ://doi.org/10.1056/NEJMe 20011 26
23. Kunling S, Yonghong Y, Tianyou W, Dongchi Z, Yi J, Runming J. Diagnosis, treatment, and prevention of 2019 novel coronavirus infection in children: experts’ consensus statement. World Journal of Pediatrics https://doi.org/10.1007/ s12519-020-00343-7.
24. Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19)-World Health Organization, Feb 28,2020.
25. World Health Organization. Clinical management of severe acute respiratory infection when Middle East Respiratory Syndrome coronavirus (MERS-CoV) infection is suspected. Interim Guidance. July 2015.
26. Arabi YM, Alothman A, Balkhy HH, Al-Dawood A, AlJohani S, Al Harbi S, et al. Treatment of Middle East Respiratory Syndrome with a combination of lopinavir-ritonavir and interferon-beta1b (MIRACLE trial): study protocol for a randomized controlled trial. Trials 2018;19(1):81.
27. Sheahan TP, Sims AC, Leist SR, Schafer A, Won J, Brown AJ, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun 2020;11(1):222.
28. Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G. A Trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19. N Engl J Med 2020 Mar 18. DOI: 10.1056/ NEJMoa2001282
29. Furuta Y, Komeno T, Nakamura T. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc Jpn Acad, Ser B, Phys Biol Sci 2017;93:449-63.
30. News. http://www.szdsyy.com/News/0a6c1e58-e3d0- 4cd1867a-d5524bc59cd6.html (accessed February 22, 2020). (in Chinese).)
31. Jianjun G, Zhenxue T , Xu Y. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Advance Publication DOI: 10.5582/bst.2020.01047
32. Audio transcript of the news briefing held by the State Council of China on February 17, 2020. The National Health Commission of the People’s Republic of China. http:// www.nhc.gov.cn/xcs/yqfkdt/202002/f12a62d10c2a48c6895cedf2faea6e1f.shtml(accessed February 18, 2020) (in Chinese).
33. Arabi YM, Arifi AA, Balkhy HH. Clinical course and outcomes of critically ill patients with Middle East respiratory syndrome coronavirus infection. Ann Intern Med 2014;160:389- 97.
34. https://www.kpwashingtonresearch.org/news-and-events/ recent-news/news 2020/kaiser-permanente-launches-coronavirus-vaccine-study-seattle) . 35. Infection prevention and control of epidemic- and pandemic-prone acute respiratory infections in health care: WHO guidelines. Geneva: World Health Organization; 2014 (http://apps.who.int/iris/ 10665/112656/, accessed 17 January 2020).
36. Minimum requirements for infection prevention and control. Geneva: World Health Organization; 2019. (Available: https://www.who.int/infection-prevention/publications/ min-req-IPC-manual/en/, accessed 20 January 2020.
37. Atkinson J, Chartier Y, Pessoa-Silva CK, Jensen P, Li Y, Seto WH, editors. Natural ventilation for infection control in health-care settings. Geneva: World Health Organization; 2009 (https://apps.who.int/iris/handle/10665/44167, accessed 17 January 2020).
38. Infection prevention and control during health care when novel coronavirus (nCoV) infection is suspected: Interim guidance. World Health Organization. 25 January 2020.
39. Decontamination and Reprocessing of Medical Devices for Health-care Facilities. Geneva: World Health Organization; 2016 (Available at: https://www.who.int/infection-prevention/publications/decontamination/en/, accessed 20 January 2020).
40. Laboratory testing for 2019 novel coronavirus (2019- nCoV) in suspected human cases: interim guidance January 2020. Geneva: World Health Organization https://www. who.int/ health-topics/coronavirus/laboratory-diagnostics-for-novel-coronavirus accessed 20 January 2020).
41. Laboratory biosafety manual, third edition. Geneva: World Health Organization; 2004 (https://apps.who.int/iris/ handle/10665/42981, accessed 17 January 2020).
42. Laboratory testing for Middle East respiratory syndrome coronavirus: interim guidance (revised), January 2018. Geneva: World Health Organization; 2018 (https://apps.who. int/iris/bitstream/handle/10665/259952/WHO-MERSLAB-15.1-Rev1-2018-eng.pdf?sequence=1, accessed 17 January 2020)
43. https://hsgm.saglik.gov.tr/tr:
44. https://www.who.int/docs/default-source/coronaviruse/ situation-reports/20200306 sitrep-46-covid-19.pdf?sfvrsn=96b04adf_2

APA	Çiftçi E, coksuer f (2020). Yeni Koronavirüs İnfeksiyonu: COVID-19. , 9 - 18. 10.5578/flora.202002
Chicago	Çiftçi Ergin,coksuer fevziye Yeni Koronavirüs İnfeksiyonu: COVID-19. (2020): 9 - 18. 10.5578/flora.202002
MLA	Çiftçi Ergin,coksuer fevziye Yeni Koronavirüs İnfeksiyonu: COVID-19. , 2020, ss.9 - 18. 10.5578/flora.202002
AMA	Çiftçi E,coksuer f Yeni Koronavirüs İnfeksiyonu: COVID-19. . 2020; 9 - 18. 10.5578/flora.202002
Vancouver	Çiftçi E,coksuer f Yeni Koronavirüs İnfeksiyonu: COVID-19. . 2020; 9 - 18. 10.5578/flora.202002
IEEE	Çiftçi E,coksuer f "Yeni Koronavirüs İnfeksiyonu: COVID-19." , ss.9 - 18, 2020. 10.5578/flora.202002
ISNAD	Çiftçi, Ergin - coksuer, fevziye. "Yeni Koronavirüs İnfeksiyonu: COVID-19". (2020), 9-18. https://doi.org/10.5578/flora.202002

APA	Çiftçi E, coksuer f (2020). Yeni Koronavirüs İnfeksiyonu: COVID-19. Flora İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Dergisi, 25(1), 9 - 18. 10.5578/flora.202002
Chicago	Çiftçi Ergin,coksuer fevziye Yeni Koronavirüs İnfeksiyonu: COVID-19. Flora İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Dergisi 25, no.1 (2020): 9 - 18. 10.5578/flora.202002
MLA	Çiftçi Ergin,coksuer fevziye Yeni Koronavirüs İnfeksiyonu: COVID-19. Flora İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Dergisi, vol.25, no.1, 2020, ss.9 - 18. 10.5578/flora.202002
AMA	Çiftçi E,coksuer f Yeni Koronavirüs İnfeksiyonu: COVID-19. Flora İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Dergisi. 2020; 25(1): 9 - 18. 10.5578/flora.202002
Vancouver	Çiftçi E,coksuer f Yeni Koronavirüs İnfeksiyonu: COVID-19. Flora İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Dergisi. 2020; 25(1): 9 - 18. 10.5578/flora.202002
IEEE	Çiftçi E,coksuer f "Yeni Koronavirüs İnfeksiyonu: COVID-19." Flora İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Dergisi, 25, ss.9 - 18, 2020. 10.5578/flora.202002
ISNAD	Çiftçi, Ergin - coksuer, fevziye. "Yeni Koronavirüs İnfeksiyonu: COVID-19". Flora İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Dergisi 25/1 (2020), 9-18. https://doi.org/10.5578/flora.202002